What ATRIUM offers you with Water Vapor Therapy

As many men get older, their prostate gland enlarges, which may squeeze the urethra and obstruct the flow of urine. Other risk factors for BPH include family history, obesity, heart disease and diabetes.1

A wide variety of treatment options are available for BPH, including watchful waiting, behavioral modification, medication, minimally invasive surgical therapies and surgery. Medication is the most common first-line treatment for mild to moderate symptoms of enlarged prostate. Minimally invasive or surgical treatment might be recommended if symptoms are moderate to severe, medication doesn’t relieve the symptoms, or the patient has other health issues.

Rezūm Therapy is an in-office treatment for men looking to treat BPH, not just the symptoms. It uses natural water vapor to reduce the size of the prostate and provide lasting symptom relief from BPH without invasive surgery or the potential side effects of prescription drugs.2 Clinical studies support that Rezūm Therapy relieves BPH symptoms safely and effectively, eliminating the need for BPH medications while also preserving sexual function.3 It helps most men see symptom improvement within a few weeks and return to regular activities within a few days after treatment.3

Clinical studies show that Rezūm Therapy provides significant lasting, improvement in symptoms and quality of life.2 It may be an option for those who have given up on watchful waiting and lifestyle changes, men who are dissatisfied with, have stopped or don’t want to start taking BPH medications, and men not interested in other minimally invasive or surgical BPH procedures. Rezūm Therapy removes excess prostate tissue with water vapor, thereby treating the disease while also relieving symptoms and preserving sexual function.3

For years, the primary options for treating BPH were through medications or invasive surgery. Rezūm Therapy is a natural, in-office therapy option for men who do not want to take medication or are dissatisfied with medication symptom relief and want to avoid invasive surgery or implants to treat their BPH. Research indicates that avoiding incontinence and preserving sexual function is a priority for men when it comes to BPH treatments.4 Clinical studies show Rezūm Therapy treats the cause of BPH symptoms while preserving sexual function and continence.2

The procedure takes place during one short office visit and does not require general anesthesia.3 During each 9-second treatment, natural water vapor is released throughout the targeted prostate tissue. When the steam contacts the tissue and turns back into water, all the stored energy is released, killing the excess prostate cells. Over time, the body’s natural healing response absorbs the dead cells and shrinks the prostate. With the extra tissue removed, the urethra opens, reducing BPH symptoms. Depending on the size of the prostate, the number of water vapor treatments vary.

Rezūm Therapy is performed in an outpatient surgical centre.

Rezūm Therapy can be performed under light IV sedation and does not require general anesthesia.3 

Rezūm Therapy is not a OHIP covered procedure however may be reimbursed by private insurance plans. Patients should verify their benefits with their individual insurance company.

Clinical studies show that most men experience symptom relief as soon as two weeks after treatment with Rezūm Therapy, and maximum benefit may occur within three months.1 As with any procedure, patient responses can vary.

Clinical studies show that following treatment with Rezūm Therapy, most men return to regular activities within a few days.3 The patient’s physician will make personal recommendations on resuming activity.

Current clinical studies demonstrate that, following treatment with Rezūm Therapy, symptom improvement is sustained through five years, and studies are ongoing to determine longer-term patient outcomes.2

Clinical studies have demonstrated that Rezūm Therapy preserves erectile and urinary functions. There were no reports of erectile dysfunction (ED) as a result of treatment with Rezūm Therapy.3 However, there is a possibility that an underlying condition may surface following treatment. Each patient should speak with a physician about their individual health situation.

In Rezūm Therapy’s clinical studies, there were no reports of post-procedure urinary incontinence as a result of treatment with Rezūm Therapy.3

All treatments have inherent and associated risks. The Rezūm System is intended to relieve symptoms and obstructions, and reduce prostate tissue associated with BPH. Potential risks include but are not limited to painful urination (dysuria), blood in the urine (hematuria), blood in the semen (hematospermia), decrease in ejaculatory volume, suspected urinary tract infection (UTI), and urinary frequency, retention or urgency. Patients should talk with their doctor about benefits and risks before moving forward with any treatment option.

Rezūm Therapy has undergone extensive clinical trials to evaluate the safety and efficacy of the treatment.2 It is now included in the American Urological Association’s BPH treatment guidelines and has five-year follow-up data showing its ability to treat prostates with hyperplasia of the central zone, lateral lobe and/or median lobe.3 Over the five years, the trial showed a surgical retreatment rate of only 4.4% and no new adverse events noted between years 1 to 5.2

Rezūm Therapy was cleared by the FDA in 2015 and is currently being used in many leading urology practices. As of 2022, more than 70,000 patients in the United States have been successfully treated with Rezūm Therapy.5

During the Rezūm Therapy pivotal study, all patients discontinued their BPH medication to ensure the efficacy seen was from Rezūm Therapy alone. As such, there has been no randomized clinical data collected on using Rezūm Therapy at the same time as BPH medications.2 

Laser therapy is an important option for patients who may not be appropriate candidates for Rezūm Therapy. Laser therapy may involve a short hospital stay and has been associated with shorter catheterization time, less bleeding and a faster recovery than traditional surgery.7-11 The individual’s medical history, health condition and other factors will influence treatment decisions.

1.  Roger K and Gilling P. Fast Facts: Benign Prostatic Hyperplasia, 7th edition. Health Press. 2011.

2.  McVary KT, Rogers T, Roehrborn CG. Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology. 2019 Apr;126:171-9.

3. McVary KT, Gange SN, Gittelman MC et al. Minimally invasive prostate convective water vapor energy (WAVE) ablation: A multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2016 May;195(5):1529-38.

4.  Boston Scientific Market Research: Understanding Today’s BPH Patient, August 30, 2018.

5.  Data on file at Boston Scientific.

6. Roehrborn CG, Barking J, Gange SM, et al. Five-year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017 Jun;24(3):8802-13.

7. Bachmann A, Tubaro A, Barber N, et al. 180-W XPS GreenLight laser vaporization versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of the European multi-centre randomized trial – The GOLIATH Study. Eur Urol. 2014 May;65(5):931-42.

8.  Lukacs B, Loeffler J, Bruyère F, et al. Photoselective vaporization of the prostate with GreenLight 120-W laser compared with monopolar transurethral resection of the prostate: A multicenter randomized controlled trial. Eur Urol. 2012;61(6):1165-73.

9.  Capitán C, Blázquez C, Martin MD, et al. GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: A randomized clinical trial with 2-year follow-up. Eur Urol. 2011 Oct;60(4):734-9.

10.  Al-Ansari A, Younes N, Sampige VP, et al. GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: a randomized clinical trial with midterm follow-up. Eur Urol. 2010 Sep;58(3):349-55.

11.  Bouchier-Hayes DM, Van Appledorn S, Bugeja P, et al. A randomized trial of photoselective vaporization of the prostate using the 80-W potassium titanyl-phosphate laser vs transurethral prostatectomy, with a 1-year follow-up. BJU Int. 2010 Apr;105(7):964-9.